While in medical school, Omar A. Ibrahimi, MD, PhD, became intrigued by dermatology. “I was struck by how dermatologists take care of newborns to the elderly, and I was impressed by how dermatologists need firm grounding in both medicine and surgery,” he says. “In the same day, they could be diagnosing a complex blistering disorder and then performing a surgical procedure. I thought that kind of...
While in medical school, Omar A. Ibrahimi, MD, PhD, became intrigued by dermatology. “...
When we think of of medical facilities, we often think of stark green walls lined by...
New Year’s resolutions are made with the best of intentions. We begin with...
Informed consent—the idea that patients have the right to make their own decisions...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 There is a new injectable neurotoxin coming to the aesthetics market. On February 1, the U.S. Food and Drug Administration approved Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) for temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or...
|
 Allergan is launching a new direct-to-consumer campaign for Botox Cosmetic (onabotulinumtoxinA) entitled “Own Your Look.” The campaign is designed to address the most common concerns around BOTOX Cosmetic—fear of looking unnatural—and to encourage people to own their looks and aesthetic choices...
|
There is a new injectable neurotoxin coming to the aesthetics market. On February 1, the U.S. Food and Drug Administration approved Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) for temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Jeuveau is a proprietary 900 kDa purified botulinum toxin type A formulation.
The approval was based on clinical data from two U.S. Phase III randomized, multi-center, double-blind, placebo-controlled clinical trials. Jeuveau met the primary endpoint and demonstrated efficacy compared with placebo in the reduction of the severity of glabellar lines in each study. The primary endpoint was defined as a 2-point composite improvement agreed upon by physician and patient at Day 30. In the trials, 67.5 percent of subjects in study one (EV-001) and 70.4 percent of subjects in study two (EV-002) met the primary endpoint, compared to 1.2 percent and 1.3 percent of patients in each placebo arm respectively.
“The outcomes I’ve seen for my clinical trial patients firsthand, combined with the comprehensive clinical data set for Jeuveau provide a compelling new treatment option for physicians and their...
Allergan is launching a new direct-to-consumer campaign for Botox Cosmetic (onabotulinumtoxinA) entitled “Own Your Look.” The campaign is designed to address the most common concerns around BOTOX Cosmetic—fear of looking unnatural—and to encourage people to own their looks and aesthetic choices.
This is the first campaign from the brand created specifically to address millennial women and men who are increasingly curious about aesthetic treatments, while continuing to speak to the BOTOX Cosmetic core consumer (women ages 34 – 45).
“As the category leader, it’s our job to continue to educate consumers about their aesthetic choices. Millennial consumers are curious about BOTOX Cosmetic, and this new campaign will modernize the iconic brand to appeal to this generation and empower them to own their looks with BOTOX Cosmetic," says Carrie Strom, senior vice president, U.S. Medical Aesthetics, Allergan. “We know there are 25 million people currently considering injectable treatments in the U.S. today, and the most common reason preventing them from getting treated is the fear of looking unnatural. The ‘Own Your Look’ campaign addresses this head-on, by showcasing real BOTOX Cosmetic users in their 20s, 30s and 40s....
Nextech Systems, a provider of healthcare technology solutions for ophthalmology, dermatology and plastic surgery practices, has acquired specialty EMR solution provider SRS Health Software. The Montvale, New Jersey-based SRS Health has developed specialized solutions across the ambulatory sector with a particular focus on Orthopedic practices.
“We are delighted to welcome SRS into the Nextech family. SRS Health’s proven success over a 20-year period in providing specialty EMR solutions and services is a perfect complement to Nextech’s long-established EMR and practice management solutions,” said Mike Scarbrough CEO of Nextech. “This is another important milestone in Nextech’s continued evolution, and we look forward to not only continuing to serve current SRS customers, but also providing additional solutions and services under the Nextech name.”
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
